1022151-47-8

Basic information

• Product Name: 3-bromoquinolin-6-yl acetate
• Synonyms: 3-bromoquinolin-6-yl acetate;6-Acetoxy-3-bromoquinoline;6-Acetoxy-3-bromoquinoline, Acetic acid 3-bromoquinolin-6-yl ester;6-Quinolinol, 3-bromo-, 6-acetate
• CAS NO: 1022151-47-8
• Molecular Formula: C₁₁H₈BrNO₂
• Molecular Weight: 266
• Mol File: 1022151-47-8.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-bromoquinolin-6-yl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromoquinolin-6-yl acetate(1022151-47-8)
• EPA Substance Registry System: 3-bromoquinolin-6-yl acetate(1022151-47-8)

Safety Data

• Hazardous Substances Data: 1022151-47-8(Hazardous Substances Data)

Usage

General Description

3-bromoquinolin-6-yl acetate is a chemical compound with the molecular formula C11H8BrNO2. It is a derivative of quinoline, a heterocyclic aromatic compound. The presence of a bromine atom at position 3 and an acetate group attached to the quinoline ring makes this compound valuable for various organic synthesis and pharmaceutical applications. It can be used as a building block in the preparation of diverse organic molecules, including pharmaceuticals, agrochemicals, and materials. Additionally, the bromine atom can serve as a site for further chemical modification, allowing for the synthesis of new compounds with potentially valuable properties. Overall, 3-bromoquinolin-6-yl acetate is an important intermediate in organic chemistry and has potential for use in drug discovery and development.

Upstream product

• 580-16-5 6-hydroxyquinoline 
• 24306-33-0 methyl quinolin-6-ylethanoate 

Downstream Products

• 1427473-83-3 1-((6-(benzyloxy)naphthalen-3-yl)methyl)-4-methylpiperazine 
• 1427473-97-9 6-(benzyloxy)-3-(4-methyl-1,4-diazepan-1-yl)quinoline 
• 1427474-50-7 6-(benzyloxy)-N-(2-(tert-butyldimethylsilyloxy)ethyl)quinolin-3-amine 
• 1427474-53-0 N-benzyl-6-(benzyloxy)quinolin-3-amine 
• 727650-61-5 3-aminoquinolin-6-ol 
• 1427474-57-4 4-(6-(benzyloxy)quinolin-3-yl)-3-methylmorpholine 
• 14036-96-5 3-bromo-6-methoxyquinoline 
• 1393352-93-6 N-((6-(benzyloxy)quinolin-3-yl)methyl)-N-ethylethanamine 
• 1393352-90-3 (S)-1-(6-(benzyloxy)quinolin-3-yl)-N,N-dimethylpyrrolidin-3-amine 
• 1337882-50-4 6-(benzyloxy)-3-bromoquinoline 
• 13669-57-3 3-bromo-6-hydroxyquinoline 

Relevant articles and documents

SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Discovery of Inhibitors of the Lipopolysaccharide Transporter MsbA: From a Screening Hit to Potent Wild-Type Gram-Negative Activity

The dramatic increase in the prevalence of multi-drug resistant Gram-negative bacterial infections and the simultaneous lack of new classes of antibiotics is projected to result in approximately 10 million deaths per year by 2050. We report on efforts to target the Gram-negative ATP-binding cassette (ABC) transporter MsbA, an essential inner membrane protein that transports lipopolysaccharide from the inner leaflet to the periplasmic face of the inner membrane. We demonstrate the improvement of a high throughput screening hit into compounds with on-target single digit micromolar (μM) minimum inhibitory concentrations against wild-type uropathogenic Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae. A 2.98 ? resolution X-ray crystal structure of MsbA complexed with an inhibitor revealed a novel mechanism for inhibition of an ABC transporter. The identification of a fully encapsulated membrane binding site in Gram-negative bacteria led to unique physicochemical property requirements for wild-type activity.

Quinoline compounds and preparation method thereof, and intermediate, pharmaceutical composition and application of quinoline compounds

The invention discloses quinoline compounds and a preparation method thereof, and an intermediate, a pharmaceutical composition and application of quinoline compounds. The invention provides quinoline compounds disclosed as Formula 1, and pharmaceutically acceptable salts, solvates, metabolites, metabolism precursors or pharmaceutical precursors thereof. The quinoline compounds have favorable inhibitory effects on tyrosine kinase C-Met, and can be used for preparing drugs for prevention, treatment or auxiliary treatment on multiple diseases related to C-Met expression or activity, and especially neoplastic diseases.